COMMUNIQUÉS West-GlobeNewswire
-
Ryoncil® Profits Underpinning Substantial Growth Pipeline
27/02/2026 -
Herz P1 Smart Ring in 2026: Features, Pricing, Accuracy Context, and What Consumers Should Verify Before Buying
27/02/2026 -
SkinnyRx GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Program, Pricing, and FDA Regulatory Status Examined
27/02/2026 -
Sprout Health NAD+ Injections — Compounding Status, Pharmacy Sourcing, and What Consumers Should Verify Before Any Telehealth NAD+ Enrollment in 2026
27/02/2026 -
Anteris Reports 2025 Financial Results and Provides Corporate Update
27/02/2026 -
HelpAlert Launches Elderly Welfare Check-In App in the United States That Requires No Wearable Device And Is Very Simple To Use.
26/02/2026 -
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
26/02/2026 -
Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA
26/02/2026 -
Longevity Supplement Primeadine® GF Named 2026 NEXTY Award Finalist by New Hope Network
26/02/2026 -
Full-year 2025 results
26/02/2026 -
Résultats annuels 2025
26/02/2026 -
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
26/02/2026 -
Flourish Research® Announces Strategic Partnership with Capitol Imaging Services and Upcoming Launch of Flourish Imaging™ in Gainesville, Georgia
26/02/2026 -
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
26/02/2026 -
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
26/02/2026 -
GENFIT : Information financière du quatrième trimestre 2025 et point sur les activités de la Société
26/02/2026 -
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
26/02/2026 -
OSE Immunotherapeutics reçoit un deuxième avis positif du Comité Indépendant de Surveillance des Données (IDMC) pour l’essai pivot de Phase 3 ARTEMIA évaluant Tedopi® dans le cancer du poumon non à petites cellules
26/02/2026 -
Trading by management and close relations of management
26/02/2026
Pages